Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ganciclovir
Drug ID BADD_D01003
Description An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
Indications and Usage For induction and maintenance in the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). Also used in the treatment of severe cytomegalovirus (CMV) disease, including CMV pneumonia, CMV gastrointestinal disease, and disseminated CMV infections, in immunocompromised patients.
Marketing Status approved; investigational
ATC Code J05AB06; S01AD09
DrugBank ID DB01004
KEGG ID D00333
MeSH ID D015774
PubChem ID 135398740
TTD Drug ID D05ARP
NDC Product Code 12806-6941; 51754-2500; 12869-803; 59651-108; 24208-535; 42023-173
UNII P9G3CKZ4P5
Synonyms Ganciclovir | Gancyclovir | BW-759 | Ganciclovir Sodium | Ganciclovir, Monosodium Salt | RS-21592 | BIOLF-62 | Cytovene
Chemical Information
Molecular Formula C9H13N5O4
CAS Registry Number 82410-32-0
SMILES C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Developmental delay19.07.05.003; 08.01.03.037--Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Drug level increased13.17.01.004--Not Available
Dry eye06.08.02.001--
Dry mouth07.06.01.002--
Dry skin23.03.03.001--
Dysaesthesia23.03.03.077; 17.02.06.003--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Dyspnoea02.11.05.003; 22.02.01.004--
Dysuria20.02.02.002--
Ear pain04.03.01.003--
Emotional disorder19.04.02.005--Not Available
Encephalopathy17.13.02.001--
Eosinophilia01.02.04.001--
Eructation07.01.02.003--
Erythema multiforme23.03.01.003; 10.01.03.015--
Euphoric mood19.04.02.006--
Eye haemorrhage12.02.02.012; 24.07.05.002; 06.07.02.001--Not Available
Eye irritation06.04.05.003--Not Available
Eye pain06.08.03.002--
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Facial paralysis17.04.03.008--Not Available
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Flatulence07.01.04.002--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 9 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene